Jodie Morrison

Chief Executive Officer

Jodie Morrison is the Chief Executive Officer of Cadent Therapeutics and is a member of Cadent’s Board of Directors. Ms. Morrison most recently served as interim Chief Executive Officer at Keryx Biopharmaceuticals, Inc. (running the process leading to the merger with Akebia Therapeutics) and Acting Chief Operating Officer at Syntimmune (acquired by Alexion).  Previously she served as President and Chief Executive Officer of Tokai Pharmaceuticals, Inc. where she took that company public in 2014. Prior to being appointed President and CEO at Tokai, Ms. Morrison held other senior positions including Chief Operating Officer and VP/Head of Clinical Affairs and Program Operations. Prior to joining Tokai, Ms. Morrison held roles in clinical operations and medical affairs at Dyax Corporation, Curis, Inc., and Diacrin, Inc. Ms. Morrison currently sits on the Board of Directors for Akebia Therapeutics (AKBA) and Aileron Therapeutics (ALRN).

Ms. Morrison received her business training through the GBEP program at the MIT Sloan School of Management,  her clinical research certification from Boston University School of Medicine and her B.A. in neuroscience from Mount Holyoke College.

Our Team

Jodie Morrison

Chief Executive Officer

Jodie Morrison is the Chief Executive Officer of Cadent Therapeutics and is a member of Cadent’s Board of Directors. Ms. Morrison most recently served as interim Chief Executive Officer at Keryx Biopharmaceuticals, Inc. (running the process leading to the merger with Akebia Therapeutics) and Acting Chief Operating Officer at Syntimmune (acquired by Alexion).  Previously she served as President and Chief Executive Officer of Tokai Pharmaceuticals, Inc. where she took that company public in 2014. Prior to being appointed President and CEO at Tokai, Ms. Morrison held other senior positions including Chief Operating Officer and VP/Head of Clinical Affairs and Program Operations. Prior to joining Tokai, Ms. Morrison held roles in clinical operations and medical affairs at Dyax Corporation, Curis, Inc., and Diacrin, Inc. Ms. Morrison currently sits on the Board of Directors for Akebia Therapeutics (AKBA) and Aileron Therapeutics (ALRN).

Ms. Morrison received her business training through the GBEP program at the MIT Sloan School of Management,  her clinical research certification from Boston University School of Medicine and her B.A. in neuroscience from Mount Holyoke College.

Our Team

Jodie Morrison

Chief Executive Officer

Jodie Morrison is the Chief Executive Officer of Cadent Therapeutics and is a member of Cadent’s Board of Directors. Ms. Morrison most recently served as interim Chief Executive Officer at Keryx Biopharmaceuticals, Inc. (running the process leading to the merger with Akebia Therapeutics) and Acting Chief Operating Officer at Syntimmune (acquired by Alexion).  Previously she served as President and Chief Executive Officer of Tokai Pharmaceuticals, Inc. where she took that company public in 2014. Prior to being appointed President and CEO at Tokai, Ms. Morrison held other senior positions including Chief Operating Officer and VP/Head of Clinical Affairs and Program Operations. Prior to joining Tokai, Ms. Morrison held roles in clinical operations and medical affairs at Dyax Corporation, Curis, Inc., and Diacrin, Inc. Ms. Morrison currently sits on the Board of Directors for Akebia Therapeutics (AKBA) and Aileron Therapeutics (ALRN).

Ms. Morrison received her business training through the GBEP program at the MIT Sloan School of Management,  her clinical research certification from Boston University School of Medicine and her B.A. in neuroscience from Mount Holyoke College.

Our Team